News, Articles and more

Clinical trials become increasingly more expensive and time-consuming. High failure rates especially in late phase trials put a substantial financial burden on healthcare systems and pharmaceutical companies. Hence, a paradigm…

In one of our recent papers, we used an AI model to predict treatment response and overall survival in intensively treated acute myeloid leukemia (AML). The article was well received…

The recent years have brought a lot of advancements in understanding leukemia biology due to comprehensive studies investigating molecular alterations. Risk stratification, however, is still largely restricted to simplistic decision-making…

Achievement of complete remission signifies a crucial milestone in the therapy of acute myeloid leukemia (AML) while refractory disease is associated with dismal outcomes. Hence, accurately identifying patients at risk…

Szymon Darius Chrost finished his Master thesis in bioinformatics with an excellent result! Szymon explored possibilities of investigating sparse patient data. In a large cohort of patients with acute myeloid…

Deep learning usually thrives on large data sets, which makes the training of classifiers in rare cancer entities rather complicated. Acute promyelocytic leukemia (APL) is a rare subform of acute…